FDA Approves New Oral Breast Cancer Treatment for Patients With ESR1 Mutations
Giredestrant combined with everolimus offers a new treatment option for certain patients with advanced hormone receptor-positive breast cancer.
The US Food and Drug Administration approved giredestrant, marketed as Wilserdly, in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed following endocrine-based treatment.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Hormone receptor-positive breast cancer is a common form of breast cancer in which tumour cells grow in response to oestrogen. Endocrine therapy is commonly used to block the effects of this hormone and slow cancer growth.
However, some patients develop mutations in the ESR1 gene. These mutations can change the behaviour of the oestrogen receptor and make cancer cells less responsive to certain hormone treatments.
On 16 November 2026, the US FDA approved giredestrant in combination with everolimus for a specific group of adults with advanced ER-positive, HER2-negative breast cancer carrying ESR1 mutations.
Giredestrant is an oral selective oestrogen receptor degrader (SERD). It works by targeting and degrading the oestrogen receptor, while everolimus acts on a separate pathway involved in tumour growth.
The approval was supported by the Phase III evERA Breast Cancer trial, which included 373 adults, including 207 patients with ESR1-mutated tumours.
In the ESR1-mutated subgroup, the combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy combined with everolimus. Median progression-free survival was approximately 10 months compared with 5.5 months.
This approval provides an additional treatment option for patients whose disease has progressed after previous endocrine-based treatment. It is specifically intended for the approved patient group and is not a treatment for every type of breast cancer.
Story Photo Gallery

Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
